Global Clonorchis Infection Market Overview:
Clonorchis is a liver fluke organism that humans can get by consumption of fish, crabs, or crayfish if these are consumed raw or undercooked. Clonorchis is mainly found across parts of Asia including South Korea, China, northern Vietnam, and far-eastern Russia, and is also known as the Chinese or oriental liver fluke. Clonorchis infect the liver, gallbladder, and bile duct in humans. In the case of clonorchis most infected persons do not show any symptoms, infections that last a long time can result in severe symptoms and serious illness. Untreated, infections may persist for up to 25–30 years, the lifespan of the parasite. The diagnosis of Clonorchis infection is based on microscopic identification of the parasite’s eggs in stool samples. In order to treat Clonorchis infections safe and effective medicines are available. Clonorchiasis is mostly prevalent in Asian countries and regions. Currently, it is projected that more than 200 million people are at risk of infection with Clonorchis.
- Increasing Incidence of Clonorchis Infections in Asia Pacific Region
- Most Infections Occur in China
- Availability of Treatment for Clonorchis Infections
- Development in Healthcare Infrastructure in Developing Regions
- Difficult in Finding Symptoms in Infected patients
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Pfizer (United States), Bayer AG (Germany), Provet (Switzerland), Virbac (India), Cipla (India), Novartis AG (Switzerland), CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India), Merck & Co., Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (United States), Arsanis, Inc. (Austria), Novabiotics (United Kingdom), GlaxoSmithKline plc. (United Kingdom) and Teva Pharmaceutical Industries Ltd (Taiwan). Analyst at AMA Research see Asian Players to retain maximum share of Global Clonorchis Infection market by 2025. Considering Market by Therapy, the sub-segment i.e. Diagnosis [Microscopic Examination, Blood Test, Imaging Examination] will boost the Clonorchis Infection market. Considering Market by Cause, the sub-segment i.e. Clonorchis Sinensis will boost the Clonorchis Infection market. Considering Market by End User, the sub-segment i.e. Hospital will boost the Clonorchis Infection market.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Clonorchis Infection market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Clonorchis Infection market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceutical Companies, Biotechnological Institutes, Government and Private Laboratories, Research and Development (R&D) Companies, Medical Research Laboratories and Market Research and Consulting Service Providers.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.